» Articles » PMID: 12453469

Regulation of Growth-related Genes by Interleukin-6 in Murine Myeloma Cells

Overview
Journal Cytokine
Date 2002 Nov 28
PMID 12453469
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukin-6 (IL-6), a pleiotropic cytokine with effects on several hematopoietic and other normal cells, is also important for the growth and survival of tumor cells such as murine plasmacytomas and human myelomas. Exploiting the 11A3 hybridoma cell line for its IL-6 requirement to proliferate in vitro, we used subtractive suppression hybridization (SSH) to identify genes whose expression is stimulated and/or repressed in response to IL-6. Northern blot analysis of 100 arbitrarily picked subtracted cDNA clones revealed that expression of 11 mRNAs were IL-6-modulated. Among these, eight were genes known to encode a variety of proteins such as enzymes (PCK, MTDNI), structural proteins (Tropoelastin), transcriptional regulators (BRG1) and proteins involved in cell division control (Cyclin A, OAZi) or cell signaling (PIX, TOPK/PBK). The recently identified MAPKK-like protein kinase TOPK/PBK gene represents a likely candidate IL-6 target gene as suggested by its significant up-regulated expression in hybridoma cells induced to grow by a brief IL-6 pulse. The diversity of growth-related genes identified in this study further emphasizes the central role of IL-6 in the regulation of myeloma cell expansion in addition to its previously demonstrated role in the inhibition of apoptosis.

Citing Articles

Comprehensive Physicochemical Characterization, In Vitro Membrane Permeation, and In Vitro Human Skin Cell Culture of a Novel TOPK Inhibitor, HI-TOPK-032.

Eedara B, Manivannan B, Alabsi W, Sun B, Curiel-Lewandrowski C, Zhang T Int J Mol Sci. 2023; 24(21).

PMID: 37958502 PMC: 10650786. DOI: 10.3390/ijms242115515.


A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle.

Li H, Dong L, Jin M, Li Q, Wang X, Jia M Molecules. 2023; 28(3).

PMID: 36770809 PMC: 9920120. DOI: 10.3390/molecules28031141.


PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.

Zhu K, Cheng X, Wang S, Zhang H, Zhang Y, Wang X Front Endocrinol (Lausanne). 2022; 12:706909.

PMID: 35126305 PMC: 8815076. DOI: 10.3389/fendo.2021.706909.


Omics- and Pharmacogenomic Evidence for the Prognostic, Regulatory, and Immune-Related Roles of PBK in a Pan-Cancer Cohort.

Liu Y, Xiang J, Peng G, Shen C Front Mol Biosci. 2021; 8:785370.

PMID: 34859058 PMC: 8632063. DOI: 10.3389/fmolb.2021.785370.


PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential.

Huang H, Lee M, Liu K, Dong Z, Ryoo Z, Kim M Cancers (Basel). 2021; 13(9).

PMID: 34066486 PMC: 8124186. DOI: 10.3390/cancers13092232.